Artwork

Contenu fourni par Matt Pillar. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Matt Pillar ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Player FM - Application Podcast
Mettez-vous hors ligne avec l'application Player FM !

T-Cells For The Win With Adaptimmune's Adrian Rawcliffe

1:01:35
 
Partager
 

Manage episode 450774628 series 2739469
Contenu fourni par Matt Pillar. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Matt Pillar ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

We love to hear from our listeners. Send us a message.

In August of this year, the first TCR cell therapy to be approved for use in the U.S. was greenlighted by the FDA for patients with unresectable or metastatic synovial sarcoma who have previously received chemotherapy. It marked the first new treatment for those patients in more than a decade; a win for those patients, and a win for Adrian Rawcliffe, who’s had a hand on the wheel at Adaptimmune, the therapy’s developer and manufacturer, since he joined the company as CFO in 2015. Today, Rawcliffe is CEO there, and on this episode of the Business of Biotech, we’re going to get to know him, why he’s all-in on cell therapies, and how he’s applying a solid track record in finance and business development to make good on the promise they offer.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

  continue reading

Chapitres

1. T-Cells For The Win With Adaptimmune's Adrian Rawcliffe (00:00:00)

2. Adrian Rockliff's Journey in Cell Therapy (00:00:04)

3. Value Creation in Cell Therapy Capabilities (00:15:41)

4. Strategic Implications of Cell Therapy Manufacturing (00:24:26)

5. Evolution of Cell Therapy Manufacturing (00:40:11)

6. Lessons From CEO on Biotech Leadership (00:47:33)

242 episodes

Artwork
iconPartager
 
Manage episode 450774628 series 2739469
Contenu fourni par Matt Pillar. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Matt Pillar ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

We love to hear from our listeners. Send us a message.

In August of this year, the first TCR cell therapy to be approved for use in the U.S. was greenlighted by the FDA for patients with unresectable or metastatic synovial sarcoma who have previously received chemotherapy. It marked the first new treatment for those patients in more than a decade; a win for those patients, and a win for Adrian Rawcliffe, who’s had a hand on the wheel at Adaptimmune, the therapy’s developer and manufacturer, since he joined the company as CFO in 2015. Today, Rawcliffe is CEO there, and on this episode of the Business of Biotech, we’re going to get to know him, why he’s all-in on cell therapies, and how he’s applying a solid track record in finance and business development to make good on the promise they offer.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

  continue reading

Chapitres

1. T-Cells For The Win With Adaptimmune's Adrian Rawcliffe (00:00:00)

2. Adrian Rockliff's Journey in Cell Therapy (00:00:04)

3. Value Creation in Cell Therapy Capabilities (00:15:41)

4. Strategic Implications of Cell Therapy Manufacturing (00:24:26)

5. Evolution of Cell Therapy Manufacturing (00:40:11)

6. Lessons From CEO on Biotech Leadership (00:47:33)

242 episodes

Tous les épisodes

×
 
Loading …

Bienvenue sur Lecteur FM!

Lecteur FM recherche sur Internet des podcasts de haute qualité que vous pourrez apprécier dès maintenant. C'est la meilleure application de podcast et fonctionne sur Android, iPhone et le Web. Inscrivez-vous pour synchroniser les abonnements sur tous les appareils.

 

Guide de référence rapide

Écoutez cette émission pendant que vous explorez
Lire